Novo Integrated Sciences Management
Management criteria checks 4/4
Novo Integrated Sciences' CEO is Rob Mattacchione, appointed in Oct 2018, has a tenure of 6.17 years. total yearly compensation is $185.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 6.54% of the company’s shares, worth $44.53K. The average tenure of the management team and the board of directors is 3.1 years and 3.8 years respectively.
Key information
Rob Mattacchione
Chief executive officer
US$185.0k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 6.2yrs |
| CEO ownership | 6.5% |
| Management average tenure | 3.1yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Slammed 49% Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Screens Well Here But There Might Be A Catch
Jul 11
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Looks Just Right With A 26% Price Jump
Apr 18Novo Integrated Sciences prices 4M unit public offering at $.50/unit
Oct 14Novo Integrated Sciences expects to report over fivefold increase in Q3 revenue
Jul 11Health Check: How Prudently Does Novo Integrated Sciences (NASDAQ:NVOS) Use Debt?
Nov 23Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?
Aug 07Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?
Mar 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Aug 31 2024 | US$185k | US$185k | -US$16m |
| May 31 2024 | n/a | n/a | -US$24m |
| Feb 29 2024 | n/a | n/a | -US$12m |
| Nov 30 2023 | n/a | n/a | -US$14m |
| Aug 31 2023 | US$185k | US$185k | -US$13m |
| May 31 2023 | n/a | n/a | -US$32m |
| Feb 28 2023 | n/a | n/a | -US$35m |
| Nov 30 2022 | n/a | n/a | -US$35m |
| Aug 31 2022 | US$185k | US$185k | -US$33m |
| May 31 2022 | n/a | n/a | -US$12m |
| Feb 28 2022 | n/a | n/a | -US$9m |
| Nov 30 2021 | n/a | n/a | -US$5m |
| Aug 31 2021 | US$47k | US$47k | -US$4m |
Compensation vs Market: Rob's total compensation ($USD185.00K) is below average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.
CEO
Rob Mattacchione (56 yo)
6.2yrs
Tenure
US$185,000
Compensation
Mr. Robert Mattacchione, also known as Rob, is Chairman of the Board and Chief Executive Officer at Novo Integrated Sciences, Inc. since October 2018. He is the Co-Owner at Mattacchione Family Trust. He is...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 6.2yrs | US$185.00k | 6.54% $ 44.5k | |
| COO & Director | 3.5yrs | US$434.56k | 0.042% $ 282.8 | |
| Principal Financial Officer & Principal Accounting Officer | 1.4yrs | no data | no data | |
| Chief Medical Officer & Chairman of Medical Advisory Board | 2.7yrs | no data | no data |
3.1yrs
Average Tenure
56yo
Average Age
Experienced Management: NVOS's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 6.2yrs | US$185.00k | 6.54% $ 44.5k | |
| COO & Director | 10.3yrs | US$434.56k | 0.042% $ 282.8 | |
| Chief Medical Officer & Chairman of Medical Advisory Board | 3.7yrs | no data | no data | |
| Member of Medical Advisory Board | 3.7yrs | no data | no data | |
| Independent Director | 3.9yrs | US$15.00k | 0% $ 0 | |
| Independent Director | 3.9yrs | no data | 0% $ 0 | |
| Member of Medical Advisory Board | 3.7yrs | no data | no data | |
| Independent Director | 2.5yrs | no data | 0% $ 0 |
3.8yrs
Average Tenure
53yo
Average Age
Experienced Board: NVOS's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 07:32 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/08/31 |
| Annual Earnings | 2024/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Novo Integrated Sciences, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|